Table 3:

Association between office blood pressure variability (OBPV) and cardiovascular disease events among ASPirin in Reducing Events in the Elderly trial participants stratified by blood pressure control status during the OBPV estimation period (N=16,475).

	BP controlled (<140/90 mmHg)				BP not controlled (BP>140/90 mmHg)
	OBPV (continuous)	OBPV Tertiles			OBPV (continuous)	OBPV Tertiles
		T1	T2	T3		T1	T2	T3
N	9328	3146	3089	3093	7147	2413	2356	2379
Observed CVD events, N (%)	222 (2.38)	61 (1.94)	75 (2.43)	86 (2.78)	275 (3.85)	68 (2.82)	86 (3.65)	121 (5.09)
	Hazard Ratio (95% CI) P-value	Referent	Hazard Ratio (95% CI) P-value	Hazard Ratio (95% CI) P-value	Hazard Ratio (95% CI) P-value	Referent	Hazard Ratio (95% CI) P-value	Hazard Ratio (95% CI) P-value
*Model 1	1.04 (1.02-1.06) P<0.001	1.00	1.24 (0.88-1.74) P=0.22	1.38 (1.00-1.92) P=0.053	1.03 (1.01-1.05) P<0.001	1.00	1.27 (0.93-1.75) P=0.14	1.80 (1.34-2.43) P<0.001
Ɨ Model 2	1.03 (1.00-1.06) P=0.016	1.00	1.17 (0.84-1.65) P=0.35	1.20 (0.86-1.67) P=0.28	1.03 (1.01-1.04) P=0.004	1.00	1.28 (0.93-1.76) P=0.13	1.66 (1.23-2.25) P=0.001
ǂModel 3	1.02 (1.00-1.05) P=0.035	1.00	1.15 (0.82-1.62) P=0.41	1.15 (0.82-1.60) P=0.42	1.03 (1.01-1.04) P=0.005	1.00	1.28 (0.93-1.76) P=0.14	1.65 (1.22-2.24) P=0.001
§ Model 4	1.02 (1.00-1.04) P=0.048	1.00	1.15 (0.82-1.61) P=0.43	1.13 (0.81-1.58) P=0.48	1.02 (1.01-1.04) P=0.01	1.00	1.27 (0.92-1.75) P=0.14	1.62 (1.20-2.20) P=0.002

BP = blood pressure; OBPV = office blood pressure variability; T = tertile; CVD = cardiovascular disease; CI = confidence interval

^*Unadjusted

^ƗAdjusted for age, sex, diabetes, smoking, country, aspirin, ethnicity, body mass index, statin use at baseline

^ǂModel 2 plus adjusted for within-individual mean systolic blood pressure from baseline to second annual visit

^§Model 3 plus adjusted for use of antihypertensive drugs at baseline